Shopping Cart 0
Cart Subtotal
USD 0

Acute Respiratory Distress Syndrome - Pipeline Review, H2 2019

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000

Details

Acute Respiratory Distress Syndrome-Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Respiratory Distress Syndrome-Pipeline Review, H2 2019, provides an overview of the Acute Respiratory Distress Syndrome (Respiratory) pipeline landscape.

Acute respiratory distress syndrome (ARDS) occurs when fluid fills up the air sacs in lungs. This leads to low oxygen levels in the blood. Common causes of ARDS include sepsis, inhalation of harmful substances, severe pneumonia and head or chest injury. Signs and symptoms of ARDS include severe shortness of breath, labored and unusually rapid breathing, low blood pressure and confusion and extreme tiredness.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Respiratory Distress Syndrome-Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Respiratory Distress Syndrome (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Acute Respiratory Distress Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 6, 14 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Acute Respiratory Distress Syndrome (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome (Respiratory).

- The pipeline guide reviews pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Acute Respiratory Distress Syndrome (Respiratory) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Acute Respiratory Distress Syndrome (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome (Respiratory) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Acute Respiratory Distress Syndrome-Overview

Acute Respiratory Distress Syndrome-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Acute Respiratory Distress Syndrome-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Acute Respiratory Distress Syndrome-Companies Involved in Therapeutics Development

Athersys Inc

Bayer AG

Cells for Cells SA

Commence Bio Inc

CompleGen Inc

Cynata Therapeutics Ltd

Emergent BioSolutions Inc

Faron Pharmaceuticals Oy

Hydra Biosciences Inc

Liminal BioSciences Inc

Meridigen Biotech Co Ltd

Northern Therapeutics Inc

Savara Inc

SolAeroMed Inc

Windtree Therapeutics Inc

Acute Respiratory Distress Syndrome-Drug Profiles

Aerosurf-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AV-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CGX-1037-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

enamptcumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Acute Respiratory Distress Syndrome-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HC-067047-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IC-14-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

imatinib mesylate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

interferon beta-1a-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IO-2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LT-1001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

molgramostim-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MSC-2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Multistem-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NAV-5093-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide for Acute Respiratory Distress Syndrome-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

plasminogen (human)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PXVX-0047-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-1229-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAN-101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

simvastatin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Soluble Guanylate Cyclase for Acute Respiratory Distress Syndrome-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Sphingosine 1-Phosphate Receptor for Acute Respiratory Distress Syndrome-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Acute Respiratory Distress Syndrome-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Acute Respiratory Distress Syndrome-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Acute Respiratory Distress Syndrome and Sepsis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TCP-25-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UMC-11912-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Acute Respiratory Distress Syndrome-Dormant Projects

Acute Respiratory Distress Syndrome-Discontinued Products

Acute Respiratory Distress Syndrome-Product Development Milestones

Featured News & Press Releases

Oct 02, 2019: Faron Pharmaceuticals announces update on Traumakine drug substance manufacturing

Aug 20, 2019: Aqualung Therapeutics receives USD 225 thousand dollar National Institute of Health (NIH) grant to establish biomarker panel for patients with acute respiratory distress syndrome

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Acute Respiratory Distress Syndrome, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019


List Of Table

List of Tables

Number of Products under Development for Acute Respiratory Distress Syndrome, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Acute Respiratory Distress Syndrome-Pipeline by Athersys Inc, H2 2019

Acute Respiratory Distress Syndrome-Pipeline by Bayer AG, H2 2019

Acute Respiratory Distress Syndrome-Pipeline by Cells for Cells SA, H2 2019

Acute Respiratory Distress Syndrome-Pipeline by Commence Bio Inc, H2 2019

Acute Respiratory Distress Syndrome-Pipeline by CompleGen Inc, H2 2019

Acute Respiratory Distress Syndrome-Pipeline by Cynata Therapeutics Ltd, H2 2019

Acute Respiratory Distress Syndrome-Pipeline by Emergent BioSolutions Inc, H2 2019

Acute Respiratory Distress Syndrome-Pipeline by Faron Pharmaceuticals Oy, H2 2019

Acute Respiratory Distress Syndrome-Pipeline by Hydra Biosciences Inc, H2 2019

Acute Respiratory Distress Syndrome-Pipeline by Liminal BioSciences Inc, H2 2019

Acute Respiratory Distress Syndrome-Pipeline by Meridigen Biotech Co Ltd, H2 2019

Acute Respiratory Distress Syndrome-Pipeline by Northern Therapeutics Inc, H2 2019

Acute Respiratory Distress Syndrome-Pipeline by Savara Inc, H2 2019

Acute Respiratory Distress Syndrome-Pipeline by SolAeroMed Inc, H2 2019

Acute Respiratory Distress Syndrome-Pipeline by Windtree Therapeutics Inc, H2 2019

Acute Respiratory Distress Syndrome-Dormant Projects, H2 2019

Acute Respiratory Distress Syndrome-Dormant Projects, H2 2019 (Contd..1), H2 2019

Acute Respiratory Distress Syndrome-Dormant Projects, H2 2019 (Contd..2), H2 2019

Acute Respiratory Distress Syndrome-Discontinued Products, H2 2019

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Acute Respiratory Distress Syndrome Therapeutic Products under Development, Key Players in Acute Respiratory Distress Syndrome Therapeutics, Acute Respiratory Distress Syndrome Pipeline Overview, Acute Respiratory Distress Syndrome Pipeline, Acute Respiratory Distress Syndrome Pipeline Assessment


Companies

Athersys Inc

Bayer AG

Cells for Cells SA

Commence Bio Inc

CompleGen Inc

Cynata Therapeutics Ltd

Emergent BioSolutions Inc

Faron Pharmaceuticals Oy

Hydra Biosciences Inc

Liminal BioSciences Inc

Meridigen Biotech Co Ltd

Northern Therapeutics Inc

Savara Inc

SolAeroMed Inc

Windtree Therapeutics Inc

Company Profile

Company Profile Title

Acute Respiratory Distress Syndrome-Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Respiratory Distress Syndrome-Pipeline Review, H2 2019, provides an overview of the Acute Respiratory Distress Syndrome (Respiratory) pipeline landscape.

Acute respiratory distress syndrome (ARDS) occurs when fluid fills up the air sacs in lungs. This leads to low oxygen levels in the blood. Common causes of ARDS include sepsis, inhalation of harmful substances, severe pneumonia and head or chest injury. Signs and symptoms of ARDS include severe shortness of breath, labored and unusually rapid breathing, low blood pressure and confusion and extreme tiredness.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Respiratory Distress Syndrome-Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Respiratory Distress Syndrome (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Acute Respiratory Distress Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 6, 14 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Acute Respiratory Distress Syndrome (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome (Respiratory).

- The pipeline guide reviews pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Acute Respiratory Distress Syndrome (Respiratory) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Acute Respiratory Distress Syndrome (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Acute Respiratory Distress Syndrome (Respiratory)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Acute Respiratory Distress Syndrome (Respiratory).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome (Respiratory) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Acute Respiratory Distress Syndrome-Overview

Acute Respiratory Distress Syndrome-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Acute Respiratory Distress Syndrome-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Acute Respiratory Distress Syndrome-Companies Involved in Therapeutics Development

Athersys Inc

Bayer AG

Cells for Cells SA

Commence Bio Inc

CompleGen Inc

Cynata Therapeutics Ltd

Emergent BioSolutions Inc

Faron Pharmaceuticals Oy

Hydra Biosciences Inc

Liminal BioSciences Inc

Meridigen Biotech Co Ltd

Northern Therapeutics Inc

Savara Inc

SolAeroMed Inc

Windtree Therapeutics Inc

Acute Respiratory Distress Syndrome-Drug Profiles

Aerosurf-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AV-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CGX-1037-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

enamptcumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Acute Respiratory Distress Syndrome-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HC-067047-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IC-14-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

imatinib mesylate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

interferon beta-1a-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IO-2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LT-1001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

molgramostim-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MSC-2-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Multistem-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NAV-5093-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptide for Acute Respiratory Distress Syndrome-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

plasminogen (human)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PXVX-0047-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

S-1229-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAN-101-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

simvastatin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Soluble Guanylate Cyclase for Acute Respiratory Distress Syndrome-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate Sphingosine 1-Phosphate Receptor for Acute Respiratory Distress Syndrome-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Acute Respiratory Distress Syndrome-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Acute Respiratory Distress Syndrome-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Acute Respiratory Distress Syndrome and Sepsis-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TCP-25-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UMC-11912-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Acute Respiratory Distress Syndrome-Dormant Projects

Acute Respiratory Distress Syndrome-Discontinued Products

Acute Respiratory Distress Syndrome-Product Development Milestones

Featured News & Press Releases

Oct 02, 2019: Faron Pharmaceuticals announces update on Traumakine drug substance manufacturing

Aug 20, 2019: Aqualung Therapeutics receives USD 225 thousand dollar National Institute of Health (NIH) grant to establish biomarker panel for patients with acute respiratory distress syndrome

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Acute Respiratory Distress Syndrome, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019


List Of Table

List of Tables

Number of Products under Development for Acute Respiratory Distress Syndrome, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Acute Respiratory Distress Syndrome-Pipeline by Athersys Inc, H2 2019

Acute Respiratory Distress Syndrome-Pipeline by Bayer AG, H2 2019

Acute Respiratory Distress Syndrome-Pipeline by Cells for Cells SA, H2 2019

Acute Respiratory Distress Syndrome-Pipeline by Commence Bio Inc, H2 2019

Acute Respiratory Distress Syndrome-Pipeline by CompleGen Inc, H2 2019

Acute Respiratory Distress Syndrome-Pipeline by Cynata Therapeutics Ltd, H2 2019

Acute Respiratory Distress Syndrome-Pipeline by Emergent BioSolutions Inc, H2 2019

Acute Respiratory Distress Syndrome-Pipeline by Faron Pharmaceuticals Oy, H2 2019

Acute Respiratory Distress Syndrome-Pipeline by Hydra Biosciences Inc, H2 2019

Acute Respiratory Distress Syndrome-Pipeline by Liminal BioSciences Inc, H2 2019

Acute Respiratory Distress Syndrome-Pipeline by Meridigen Biotech Co Ltd, H2 2019

Acute Respiratory Distress Syndrome-Pipeline by Northern Therapeutics Inc, H2 2019

Acute Respiratory Distress Syndrome-Pipeline by Savara Inc, H2 2019

Acute Respiratory Distress Syndrome-Pipeline by SolAeroMed Inc, H2 2019

Acute Respiratory Distress Syndrome-Pipeline by Windtree Therapeutics Inc, H2 2019

Acute Respiratory Distress Syndrome-Dormant Projects, H2 2019

Acute Respiratory Distress Syndrome-Dormant Projects, H2 2019 (Contd..1), H2 2019

Acute Respiratory Distress Syndrome-Dormant Projects, H2 2019 (Contd..2), H2 2019

Acute Respiratory Distress Syndrome-Discontinued Products, H2 2019

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Acute Respiratory Distress Syndrome Therapeutic Products under Development, Key Players in Acute Respiratory Distress Syndrome Therapeutics, Acute Respiratory Distress Syndrome Pipeline Overview, Acute Respiratory Distress Syndrome Pipeline, Acute Respiratory Distress Syndrome Pipeline Assessment


Companies

Athersys Inc

Bayer AG

Cells for Cells SA

Commence Bio Inc

CompleGen Inc

Cynata Therapeutics Ltd

Emergent BioSolutions Inc

Faron Pharmaceuticals Oy

Hydra Biosciences Inc

Liminal BioSciences Inc

Meridigen Biotech Co Ltd

Northern Therapeutics Inc

Savara Inc

SolAeroMed Inc

Windtree Therapeutics Inc